Therapy for Viral Hepatitis and Prevention of Hepatocelluar Carcinoma

by Omata, M.; Okita, K.

• ISBN13: 9784431402800
• ISBN10: 4431402802
• Format: Hardcover
• Copyright: 2004-01-01
• Publisher: Springer Verlag

Summary

The first single-topic annual conference on hepatology in Japan was held in November 2002 to discuss therapies for viral hepatitis and the prevention of hepatocellular carcinoma (HCC). Bringing together researchers and clinicians from North America, Europe, Japan, and other parts of Asia, the conference included symposia on the hepatitis C replicon system, new antivirals that lower or prevent the incidence of HCC, and transplantation in cases of hepatitis B and C, as well as new treatment modalities for viral hepatitis and preventative measures for HCC. With the rising number of HCC cases worldwide, this collection of papers presented at the conference provides a valuable, up-to-date resource and reference for all professionals involved in the treatment and prevention of viral hepatitis and hepatocellular carcinoma.

Table of Contents

Inaugurating the Single-Topic Conference	v
Preface	vii
Organization of the Symposium	xi
1 Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma
1.1 Opening Lecture: What is Accomplished and What is Needed
M. OMATA	3	(22)
2 Lamivudine Therapy for Hepatitis B
2.1 New Anti-Virals Against Wild-Type and Lamivudine-Resistant Hepatitis B Virus
N. KATO, S.K. ONO-NITA, and M. OMATA	25	(7)
2.2 Lamivudine Therapy of Hepatitis B in Japan
M. SATA	32	(6)
2.3 Early Detection of Lamivudine Resistant Mutant in Chronic Hepatitis B Patients Using a Novel Sensitive Method
T. OKANOUE, K. MORI, T. KIRISHIMA, and M. MINAMI	38	(9)
3 New Anti-Virals: HBV
3.1 New Antiviral Treatment for Chronic Hepatitis B
M.-F. YUEN and C.-L. LAI	47	(10)
3.2 New Antiviral Therapy: Adefovir Dipivoxil for HBV
M. PETERS	57	(6)
3.3 Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection
D. DEHERTOGH, R. COLONNO, W. FISKE, and A. CROSS	63	(14)
4 Therapy for Hepatitis B and Prevention of HCC
4.1 Therapy of Hepatitis B and Prevention of Hepatocellular Carcinoma
N. LEUNG	77	(7)
4.2 Differences of Clinical Characteristics Among Japanese Patients with Hepatitis B Virus Genotypes B and C
M. MIZOKAMI and E. ORITO	84	(13)
5 HCV Replicon System
5.1 Establishment of a New Hepatitis C Virus-lb Replicon
N. ENOMOTO, N. SAKAMOTO, M. KUROSAKI, S. MAEKAWA, Y. TANABE, T. YAMASHIRO, C.-H. CHEN, M. NAKAGAWA, N. KANAZAWA, H. WATANABE, C. SATO, and M. WATANABE	97	(11)
5.2 Hepatitis C Virus Replication in Cell Culture
M. FRESE, V. LOHMANN, T. PIETSCHMANN, A. KAUL, N. KRIEGER, J. BUKH, and R. BARTENSCHLAGER	108	(15)
5.3 Characterization of the Interferon Alpha Response Against HCV in Hepatoma Cells
C. SEEGER, Q. ZHU, and J.-T. Guo	123	(10)
6 New Anti-Virals: HCV
6.1 Hepatitis C: Development of a Ribavirin Liver-Targeting Prodrug
J.Y.N. LAU	133	(7)
6.2 HCV Replicon Inhibitors: Mode of Action and Resistance Mapping
R.T. SARISKY	140	(17)
7 Interferon Therapy for Hepatitis C
7.1 Interferon Treatment Not Only Reduces the Risk of Hepatocellular Carcinoma But Also Improves Mortality in Patients with Chronic Hepatitis C Showing Biochemical Response, Especially in Patients with Advanced Liver Fibrosis
A. KASAHARA and N. HAYASHI	157	(10)
7.2 Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon
O. YOKOSUKA, F. IMAZEKI, S. KAWAI, and K. FUKAI	167	(9)
7.3 IFN Receptor and IFN Signals
H. YATSUHASHI	176	(13)
8 Therapy for Hepatitis C and Prevention of HCC
8.1 Management and Treatment of Hepatitis C
L.B. SEEFF	189	(10)
8.2 Hepatitis C Virus and Hepatocellular Carcinoma
M.J. TONG	199	(10)
8.3 Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome
S. NISHIGUCHI and S. KUBO	209	(10)
8.4 Roles of Antiviral Therapy in Chronic Hepatitis C Patients Should be Different According to the Stages of Liver Disease Progression
Y. SHIRATORI	219	(10)
8.5 Significance of Sustained Inflammation in the Development of HCC from HCV-Associated Cirrhotic Patients and the Prevention of HCC by Anti-Inflammatory Agents
K. TARAO	229	(12)
9 Chemoprevention and Therapy for HCC
9.1 Chemoprevention of Hepatocellular Carcinoma with Retinoid
H. MORIWAKI	241	(8)
9.2 Vitamin K2 Administration Improves the Prognoses of Patients with Hepatocellular Carcinoma Presenting High Levels of Serum Des-γ-Carboxy Prothrombin
Y. KOIKE, Y. SHIRATORI, H. YOSHIDA, and M. OMATA	249	(2)
9.3 Combination Chemotherapy for Advanced Hepatocellular Carcinoma
S. KANEKO	251	(7)
9.4 Combined Intra-Arterial 5-Fluorouracil and Subcutaneous Interferon-Alpha Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombi in the Major Portal Branches
M. MONDEN, M. SAKON, and H. NAGANO	258	(15)
10 Transplantation for HBV and HCV
10.1 Liver Transplantation for Hepatitis B Virus-Related Liver Disease
S.B. PORTER and K.R. REDDY	273	(10)
10.2 Living Donor Liver Transplantation for Hepatitis B and C Cirrhosis
Y. SUGAWARA and M. MAKUUCHI	283	(10)
10.3 Living Donor Liver Transplantation for HBV-/HCV-Related Diseases
T. KIUCHI and K. TANAKA	293